Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
説明 | TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others. |
ターゲット&IC50 | FGR:<2.0 nM, c-Src:1.3 nM, CLK2:<2.0 nM, YES1:<2.0 nM, JAK3:1.2 nM |
別名 | TAK901 |
分子量 | 504.64 |
分子式 | C28H32N4O3S |
CAS No. | 934541-31-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (184.3 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TAK-901 934541-31-8 Angiogenesis Cell Cycle/Checkpoint Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors CDK JAK Aurora Kinase Src TAK 901 Inhibitor TAK901 inhibit inhibitor